메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Neurabody Enters the UK Market with Selfridges Launch, Sho…

LONDON, Dec. 15, 2025 -- Neurabody, the AI-driven posture science company transforming modern ergonomics, today announced its official launch at Selfridges London, marking a significant milestone in the company's global expansion and consumer entry into the UK market. With this debut, Selfridges customers will experience NeuraSit, Neurabody's intelligent posture-support system that merges ergonomic engineering, embedded sensors, and real-time AI feedback to help users improve posture effortlessly. The product will be featured within Selfridges' curated mix of forward-thinking t
- 김갑성 기자
- 2025-12-15 22:00
Lunit Announces Collaboration with Daiichi Sankyo to Advan…

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs. Da
- 김갑성 기자
- 2025-12-15 22:00
피엠인터내셔널, 후원 아동 8천 명으로 확대…288만 유로 기부로 사회 공헌 리더십 강화

솅겐, 룩셈부르크, 2025년 12월 15일 -- 피엠인터내셔널(이하 PMI, Founder & CEO 롤프 소르그 회장)이 자선 재단인 'PM 위 케어(PM We Care)'를 통해 자선 나눔 활동 확대에 나섰다. PMI는 2026년까지 국제구호개발 월드비전과의 파트너십을 강화하고, 1,400명의 아동을 추가로 후원하여 총 후원 아동 수를 8,000명으로 늘리고 연간 기부금 역시 288만 288만 유로(약 39억 원)로 증액해 프로그램을 더욱 공고히 할 계획이다. 월드비전에 따르면, 전 세계 정부와 기관들이 아동 지원 기금을 163억 달러(한화 약 22조 원) 삭감하면서 수백만 명의 취약계층 아동들이 식량을 비롯한 의료 서비스 등의 접근에 제한을 받고 있는 것으로 나타났다. PMI 비키 소르그 자선 대사는 "모든 '피트라인' 제품 구매는 전 세계의 팀파트너들이 후원 아동에게 '한 시간의 삶'을 선물하는 것"이라며 "우리는 계속해서 월드비전의 든든한 파트너가 되고자 한다"고 전했다. Picture is available at AP 담당자 정보
- 김갑성 기자
- 2025-12-15 22:00
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinic…

SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona's INHBE program. Scientific and industry interest in INHBE has accelerated, supported by compelling human genetic evidence and emerg
- 김갑성 기자
- 2025-12-15 21:00
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announ…

TAIPEI, Dec. 15, 2025 -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research and industrial applications. The integration provides Leadgene Biosolutions with a clear direction and expanded opportunities in
- 김갑성 기자
- 2025-12-15 21:00
Curie Oncology and Oncoshot Deploy AI to Improve Patient Ou…

SINGAPORE, Dec. 15, 2025 -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials. The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system. Curie Oncology: using AI to bring more trials to patients Curie Oncology currently r
- 김갑성 기자
- 2025-12-15 19:26
Minghui Pharmaceutical Announces FDA clearance of IND to…

SHANGHAI and HANGZHOU, China, Dec. 15, 2025 -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application to initiate global Phase Ⅲ clinical trials of MHB018A for the treatment of thyroid eye disease (TED). The trials in both active and chronic TED are randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy and safety of subcutaneous MHB018A administered every four
- 김갑성 기자
- 2025-12-15 18:00
Ascletis Announces Positive Topline Results from U.S. Phase…

- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, indicated by elevated plasma interleukin-17A (IL-17A) levels, which continued until day 7 for higher doses of ASC50. - ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg in single ascending dose study in healthy participants. - ASC50 was safe and we
- 김갑성 기자
- 2025-12-15 17:00
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Compa…

[ 메디채널 김갑성 기자 ] The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia SAN ANTONIO, Dec. 15, 2025 -- Frost & Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been honored with the 2025 Southeast Asia Company of the Year Recognition in the stem cell banking and regenerative medicine industry for its outstanding achievements in innovation, regulatory leadership, and clinical alignment. This recognition highlights MEDEZE's leadership in advancing the next gener
- 김갑성 기자
- 2025-12-15 17:00
Global Spotlight｜POGMENT Biomimetic Collagen "Stable Triple H…

CHENGDU, China, Dec. 15, 2025 -- Recently, LivingPhoenix Regenerative Technologies has captured widespread attention with its world-first "Stable Triple-Helix Biomimetic Collagen" technology, making consecutive appearances at 12 high-level academic conferences in November. These events spanned aesthetic medicine, regenerative medicine, and personal care. Several academicians and industry experts have unanimously hailed the innovation as a mark of collagen R&D's evolution from "animal extraction" and "genetic recombination" to "structural design." Re
- 김갑성 기자
- 2025-12-15 16:32

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 17시 40분